RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0037-1601454
Evaluation of Probably Benign Adnexal Masses in Postmenopausal Women
Avaliação de massas anexiais benignas em mulheres pós-menopáusicasPublikationsverlauf
08. Oktober 2016
06. Januar 2017
Publikationsdatum:
27. März 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00030576/201705/lookinside/thumbnails/10-1055-s-0037-1601454_5887-1.jpg)
Abstract
Background Preoperatively identification of malignancy potential of a postmenopausal adnexal masses is important.
Aim To evaluate the effectiveness of the Risk of Malignancy Index-2 in presumably benign adnexal masses in postmenopausal women.
Study Design Retrospective, observational study.
Methods 119 women with postmenopausal adnexal masses with a preliminary diagnosis of benign tumors according to the Risk of Malignancy Index-2 were included. Age, duration of menopause, ultrasonographic findings, and serum CA-125 levels were recorded preoperatively. The definitive diagnosis was based on postoperative histopathological examination.
Results Of 119 adnexal mass, 10 were malignant and 109 were benign. There was no statistically significant difference with regard to age and tumor size between the groups. The two significant ultrasonographic parameter between groups were the presence of solid area in the mass and bilaterality. Moreover, if the cut off point for serum CA-125 was adjusted to 14.75 IU/mL according to ROC curve, a sensitivity value of 80% and a specificity value of 72% could be achieved to discriminate benign and malign cysts.
Conclusion In the differential diagnosis of benign and malignant adnexal masses in postmenopausal women, the presence of a solid component, bilaterallity based on ultrasonography and high CA-125 values may be used as discriminative criteria. There is no direct relation between the size of the adnexal mass and malignancy potential. Therefore, in the malignancy indexes of postmenopausal women, we recommend lower cut-off values of CA-125 to increase the sensitivity of preoperative evaluation tests without having a great impact on negative predictive values.
Resumo
Introdução É fundamental identificar o potencial maligno de massas anexiais pós-menopáusicas no período pré-operatório.
Objetivo Avaliar a efetividade do risco de malignidade (risk of malignancy index-2, RMI2) em massas anexiais benignas presumíveis em mulheres na pós-menopausa.
Desenho do Estudo Estudo observacional retrospectivo.
Métodos Este estudo foi conduzido em nossa clínica de cirurgia de endoscopia e endoscopia de nosso hospital entre janeiro de 2013 e setembro de 2015. Um total de 119 mulheres com massas anexiais pós-menopausa com diagnóstico preliminar de tumores benignos de acordo com o RMI-2. A idade, a duração da menopausa, os achados ultrassonográficos e os níveis séricos de CA-125 foram registados no pré-operatório. O diagnóstico definitivo foi baseado no exame histopatológico pós-operatório.
Resultados A média de idade dos pacientes foi de 55,4 ± 6,71 anos. O exame histopatológico revelou que 8,4% das massas anexiais eram tumores malignos ou limítrofes, enquanto 91,6% eram benignos. Não houve diferença estatisticamente significante quanto ao tamanho do tumor e do tamanho das lesões entre patologias malignas e benignas. Não houve diferença estatisticamente significativa entre pacientes benignos e malignos quanto à idade e tamanho do tumor. Os dois parâmetros ultra-sonográficos estatisticamente significativos entre os grupos foram a presença de área sólida na massa e bilateralidade. Além disso, se o ponto de corte para CA-125 sérico fosse ajustado para 14,75 UI/mL de acordo com a curva receiver operating characteristic (ROC), um valor de sensibilidade de 80% e um valor de especificidade de 72% poderiam ser conseguidos para discriminar cistos benignos e malignos (área sob a curva [ASC]: 0,89).
Conclusão No diagnóstico diferencial de massas anexiais benignas e malignas em mulheres pós-menopáusicas, a presença de um componente sólido, bilaterais com base na ultra-sonografia e valores elevados de CA-125 podem ser utilizados como critério discriminatório. Parece que não há relação direta entre o tamanho da massa anexial eo potencial maligno. Portanto, nos índices de malignidade de mulheres pós-menopáusicas, recomendamos valores de corte mais baixos de CA-125 para aumentar a sensibilidade dos testes de avaliação pré-operatória sem ter grande impacto em valores preditivos negativos.
-
References
- 1 Rufford B. Ovarian cysts in postmenopausal women. London: Royal College of Obstetricians and Gynaecologists; 2012. Green-top Guideline No. 34)
- 2 Dørum A, Blom GP, Ekerhovd E, Granberg S. Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol 2005; 192 (01) 48-54
- 3 Goldstein SR, Subramanyam B, Snyder JR, Beller U, Raghavendra BN, Beckman EM. The postmenopausal cystic adnexal mass: the potential role of ultrasound in conservative management. Obstet Gynecol 1989; 73 (01) 8-10
- 4 Morgan A. Adnexal mass evaluation in the emergency department. Emerg Med Clin North Am 2001; 19 (03) 799-816
- 5 Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010; 102 (04) 222-229
- 6 Brown DL, Dudiak KM, Laing FC. Adnexal masses: US characterization and reporting. Radiology 2010; 254 (02) 342-354
- 7 Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993; 100 (10) 927-931
- 8 Biggs WS, Marks ST. Diagnosis and management of adnexal masses. Am Fam Physician 2016; 93 (08) 676-681
- 9 Vergote I, De Brabanter J, Fyles A. , et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357 (9251): 176-182
- 10 Carley ME, Klingele CJ, Gebhart JB, Webb MJ, Wilson TO. Laparoscopy versus laparotomy in the management of benign unilateral adnexal masses. J Am Assoc Gynecol Laparosc 2002; 9 (03) 321-326
- 11 Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers - a Cochrane systematic review. Gynecol Oncol 2012; 126 (02) 286-290
- 12 Bast Jr RC, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22 (Suppl. 01) S5-S8
- 13 Timmerman D, Testa AC, Bourne T. , et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008; 31 (06) 681-690
- 14 Timmerman D, Testa AC, Bourne T. , et al; International Ovarian Tumor Analysis Group. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 2005; 23 (34) 8794-8801
- 15 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97 (10) 922-929
- 16 Tingulstad S, Hagen B, Skjeldestad FE. , et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996; 103 (08) 826-831
- 17 Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999; 93 (03) 448-452
- 18 Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 2009; 144 (02) 163-167
- 19 Cure MC, Cure E, Kirbas A, Yazici T, Yuce S. Requests for tumor marker tests in Turkey without indications and frequency of elevation in benign conditions. Asian Pac J Cancer Prev 2012; 13 (12) 6485-6489
- 20 Obeidat BR, Amarin ZO, Latimer JA, Crawford RA. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet 2004; 85 (03) 255-258
- 21 Ashrafgangooei T, Rezaeezadeh M. Risk of malignancy index in preoperative evaluation of pelvic masses. Asian Pac J Cancer Prev 2011; 12 (07) 1727-1730
- 22 American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117 (03) 742-746
- 23 Kaijser J, Bourne T, Valentin L. , et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013; 41 (01) 9-20
- 24 Testa A, Kaijser J, Wynants L. , et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. Br J Cancer 2014; 111 (04) 680-688